Clinical trials: Pulmonary Aspergillosis
Aspergillosis, Candidemia
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.
- Trial name
- NCT00940017
- Testing
- anidulafungin and voriconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Infection, Invasive Pulmonary Aspergillosis
Early Diagnosis of Invasive Lung Aspergillosis
The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on oncological diseases and their therapy, but mainly due to a rise in…
- Trial name
- NCT05860387
- Testing
- Next generation improvement of early invasive aspergillosis
- Where
- 7 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Ostrava
Chronic Pulmonary Aspergillosis, Aspergillosis
Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study
This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients with chronic lung…
- Trial name
- INCAS (NCT05653193)
- Testing
- Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care, Antifungals as standard of care
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Manchester University NHS Foundation Trust
Liver Cirrhosis, Viral Pneumonia
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors
Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection of the respiratory system, caused by a specific fungus called Aspergillus species.
- Conditions
- Liver Cirrhosis, Viral Pneumonia, Fungal Infection, Invasive Pulmonary Aspergillosis
- Trial name
- LIVERIPA (NCT07238114)
- Where
- Belgium
- Volunteers
- 450 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Invasive Pulmonary Aspergillosis
Diagnosis of Invasive Pulmonary Aspergillosis, Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid
The aim of this research project is to compare the results of Aspergillus specific test methods Aspergillus Galactomannan Enzyme Immunoassay (GM-EIA), Aspergillus polymerase chain reaction (PCR), Aspergillus Galactomannan Lateral…
- Trial name
- DipA2 (NCT04848831)
- Volunteers
- 100 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Hematologic Disease, Solid Organ Transplantation
Radiologic Features of Invasive Pulmonary Aspergillosis
Invasive pulmonary aspergillosis (IPA) is an opportunistic infection that primarily affects recipients of solid organ transplants (SOTs) and patients with chemotherapy- induced neutropenia.Although both of these populations are…
- Trial name
- NCT01178177
- Volunteers
- 130 people
- Sponsor
- Asan Medical Center
Aspergillosis, Cystic Fibrosis
The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
This study tests the effects of an experimental drug PC945 in people with cystic fibrosis whose lungs are infected by the fungus Aspergillus fumigatus.
- Trial name
- NCT03870841
- Testing
- PC945
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Pulmocide Ltd
Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities.
- Trial name
- GLITZ (NCT05444946)
- Testing
- Prednisone tablet and Itraconazole, Oral itraconazole
- Where
- 2 sites in India
- Volunteers
- 104 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Allergic Bronchopulmonary Aspergillosis
Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by a complex hypersensitivity response to antigens released by the fungus Aspergillus fumigatus.
- Trial name
- NCT00974766
- Testing
- Glucocorticoids
- Where
- India
- Volunteers
- 92 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Pulmonary Aspergillosis
A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis
The current initial therapy for CPA is with six months of oral itraconazole. However, the response with six months of therapy has a response rate of 65-70% and has a relapse rate after stopping treatment of up to 50%.
- Trial name
- NCT04824417
- Testing
- Itraconazole 200 mg, Voriconazole 200mg
- Where
- 2 sites in India
- Volunteers
- 116 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Pulmonary Aspergillosis
Aspergillus-specific IgG Assays for the Diagnosis of Chronic Pulmonary Aspergillosis (CPA)-Multicenter Study
Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA)
- Trial name
- NCT03027089
- Where
- China
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Pulmonary Aspergillosis
Azole-resistance in Aspergillus
Prospective multi-center surveillance study on the prevalence of azole-resistant Aspergillus spp. in clinical isolates of patients with pulmonary colonization or invasive infections in Switzerland
- Trial name
- NCT03443336
- Where
- Switzerland
- Volunteers
- 400 people
- Sponsor
- University Hospital, Basel, Switzerland
Aspergillosis, Lung Diseases, Fungal
A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma
To compare the safety and effectiveness of itraconazole oral solution to placebo in the treatment of a pulmonary aspergilloma. Aspergilloma is a "fungal ball" in the lungs caused by Aspergillus.
- Trial name
- NCT00005668
- Testing
- Itraconazole oral solution
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergic Broncho-Pulmonary Aspergillosis
Protocol TARC-ABPA
The main objective of this study is to determine if a doubling of serum TARC (compared to baseline) is associated with the occurrence of exacerbations of ABPA. The secondary objectives of the study are : 1.
- Trial name
- NCT01710930
- Testing
- Study of predictive factors
- Where
- 2 sites in France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital
Allergic Bronchopulmonary Aspergillosis, Asthma
Allergic Bronchopulmonary Aspergillosis Prescreening Study
This prescreening study is being conducted to diagnose ABPA in selected patients with asthma and to increase the potential number of eligible participants for the ongoing Study 601-0018 of PUR1900 in subjects with ABPA.
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Asthma, ABPA
- Trial name
- NCT05903612
- Where
- United Kingdom
- Sponsor
- Community Pharmacology Services Ltd
Pulmonary Aspergillosis
An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
A study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
- Trial name
- NCT05037851
- Testing
- Opelconazole, Standard of Care
- Where
- 19 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Pulmocide Ltd
Thymus and Activation Regulated Chemokine
Role of Thymus-And Activation-Regulated Chemokine (TARC) In Diagnosis Of Allergic Bronchopulmonary Aspergillosis
This study aims to assess the value of TARC in diagnosis of allergic Bronchopulmonary Aspergillosis.
- Trial name
- NCT03267394
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Allergic Bronchopulmonary Aspergillosis
Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
The purpose of this study is to evaluate the efficacy and safety of itraconazole monotherapy in patients with ABPA.
- Trial name
- MIPA (NCT01321827)
- Testing
- Glucocorticoids, Itraconazole
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Invasive Pulmonary Aspergillosis
CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients
To investigate the relationship between cytochrome P450 (CYP) 2C19 genetic polymorphism and the steady-state blood concentration of voriconazole in Chinese patients with invasive pulmonary aspergillosis (IPA), and to assess the…
- Trial name
- NCT02100761
- Testing
- Voriconazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- dingshifang
Chronic Pulmonary Aspergillosis
Six Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With CPA
The treatment options majorly consist of medical management with at least 6-month long treatment with antifungal drugs - most significantly the azole groups. Itraconazole is the preferred azole for the treatment of CPA.
- Trial name
- NCT03920527
- Testing
- Itraconazole 400 mg
- Where
- India
- Volunteers
- 164 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh